Background: Chronic inflammation in ulcerative colitis (UC) patients is the major risk factor for colitis-associated colon cancer (CAC). Recent evidences have shown that microRNAs (miRNAs) are implicated in CAC pathogenesis. However, the interaction of miRNAs with the transcription factors that alleviate CAC has not been reported. Methods: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 3,3′-diindolylmethane (DIM) were used to activate aryl hydrocarbon receptor (Ahr) in azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CAC in mice. Realtime PCR was used to quantify the mRNAs of miRNA and coding genes while western blot and ELISA were used to quantify protein levels. Silencing miRNA was carried out by means of electroporation and locked nucleic acid (LNA)-miRNA. Results: Inducing CAC in mice upregulated miR-132 expression in the colon, spleen and lymph nodes at all stages of disease development. Activation of Ahr by TCDD or DIM boosted miR-132 expression and alleviated CAC severity by suppression of macrophage infiltration and pro-inflammatory cytokines. Interestingly, TCDD, but not DIM, augmented a cholinergic anti-inflammation by inducing acetylcholinesterase (AChE)-targeting miR-132. This anti-inflammation was manifested by suppressed production of TNF-α, IL-1β and IL-6. Silencing miR-132 in vivo in TCDD-treated mice abrogated the cholinergic anti-inflammation and exacerbated CAC. In addition, inhibition of miR-132 in vitro in CD4 + cells and macrophages mitigated the inhibitory effect of TCDD on AChE catalytic activity. Conclusion: Our findings identify miR-132 as a new molecule implicated in CAC pathogenesis, and reveal that miR-132 mediates the ameliorating effects of TCDD on CAC, suggesting miR-132 as a promising therapeutic candidate to control autoimmune inflammation and tumorigenesis in CAC patients.
Introduction
Colorectal cancer exemplifies the fundamental link between chronic inflammation and tumorigenesis. Patients with inflammatory bowel disease (IBD) such ulcerative colitis (UC) have much higher risk (~30 folds) to develop colon cancer [1] . Therefore, the IBD-associated dysplasia and colon cancer embodies a major complication in patients with IBD [2] . The colitis-associated colon cancer (CAC) is an inflammationdysplasia-carcinoma that shows higher malignancy and decreases life expectancy compared with sporadic colon cancer [3] . Previous studies have elucidated transcriptional and posttranscriptional mechanisms for the pathophysiological process of CAC [4, 5] . However, a clear strategy to control CAC development is yet to be established.
The microRNAs (miRNAs) are short nucleotides that regulate the transcriptome at the posttranscriptional level by complementary binding to the 3′ untranslated region (3′UTR) of the target mRNA. A recently formed paradigm has clearly linked numerous miRNAs with tumorigenesis of several tumors such as gastric, lung and breast cancer [6, 7, 8] . The miRNAs such as miR-543 and miR-517 enhance tumorigenesis of colon cancer by targeting phosphatase and tensin homolog (PTEN) and forkhead box J3 (FOXJ3), respectively [9, 10] . In contrast, miR-320 suppresses colon cancer by targeting SRY-related HMG-box4 (SOX4), FOXM1 and FOXQ1 [11] . In animal model of CAC, deletion of miR-155 exacerbates disease conditions by greater activation of transforming growth factor-β (TGF-β)/SMAD pathway [12] . Furthermore, inhibition of miR-214 in CAC mice reduces inflammation and tumor by increasing PTEN, PDZ and LIM domain 2 (PDLIM2) [13] .
MiR-132 is a highly conserved miRNA belonging to a cluster named miR-212/132. Several studies have shown that miR-132 suppresses breast [14] , ovarian [15] , and prostate [16] cancers. In colon cancer, miR-132 inhibits metastasis and cell invasion of different colon cancer cell lines by targeting zinc finger E-box-binding homeobox 2 (ZEB2) [17] . Furthermore, inhibition of miR-132 is associated with poor prognosis and enhanced cell invasion in colorectal cancer [18, 19] . Several studies have demonstrated an anti-inflammatory role of miR-132 in different inflammatory immune responses [20, 21, 22] . This antiinflammatory role is attributed mainly to targeting acetylcholinesterase (AChE) that hydrolyzes acetylcholine (ACh), a neurotransmitter that suppresses pro-inflammatory cytokines by interrupting nuclear factor κB (NFκB) nuclear translocation [23] . In addition, AChE enhances anchorage independent growth of colon cancer [24] . Although miR-132 possesses anti-inflammatory and anti-tumor properties in colon cancer, its implication in CAC has not previously been explored.
Recently, we showed that the expression of miR-212/132 cluster is regulated by aryl hydrocarbon receptor (Ahr) [25, 26, 27] which is an environmentally-responsive transcription factor. This heterodimeric transcription factor acts as a tumor suppressor in inflammation-associated intestinal neoplasia [28] . Importantly, activation of Ahr by exogenous ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 3,3′-diindolylmethane (DIM) attenuates the inflammatory symptoms of UC [29, 30] , and its activation by indole-3-carbinol (I3C) suppresses CAC in mice [31] . Notably, the TCDD-activated Ahr induces miR-132/AChE module and augments cholinergic anti-inflammatory mechanism or scheme characterized by suppression of pro-inflammatory cytokines [21] . Therefore, we hypothesized that ligandactivated Ahr could induce the miR-132/AChE axis to suppress development of CAC.
To examine this hypothesis, the effect of TCDD and DIM on CAC pathogenesis and miR-132 expression was investigated in mice. Our data identified miR-132 as a new molecule implicated in CAC development, and revealed that TCDD alleviates CAC by augmenting a cholinergic anti-inflammation via enhancing the expression of AChEtargeting miR-132.
Materials and methods

Animals
Female 8-10 weeks old C57BL/6 mice were purchased originally from Charles River and maintained in specific-pathogen-free (SPF) conditions. The experiments were performed at the animal housing unit and the Physiology Laboratory in the College of Science, King Faisal University, Saudi Arabia, in accordance with the protocol approved by the Standing Research Ethics Committee.
CAC model and treatments
The CAC was induced by an adopted method described by Thaker et al. [32] . Briefly, the mice were injected i.p. with azoxymethane (AOM; Sigma Aldrich, MO, USA) at 7.5 mg/kg on day -7, and received 2.5 % dextran sodium sulfate (DSS; MP Biomedicals, CA, USA) in drinking water on day 0-5 followed by 16 days of tap water. The cycle of DSS and tap water was repeated 3 times. The mice were injected i.p. with TCDD (1 μg; AccuStandard, CT, USA), DIM (25 μg; Sigma Aldrich) or corn oil (Sigma Aldrich) 2 days before DSS treatment. Disease activity index (DAI) score that includes weight loss, stool consistency and anal bleeding was calculated as described previously [33] . On day 63, the mice were euthanized for samples collection. The number and size of tumor nodules in the excised colons examined using a dissection microscope and Vernier caliper [32] .
Histological studies
The sections from distal colon stained by the conventional hematoxylin & eosin (H & E) staining procedure. A pathologist who is blind of the experimental treatments calculated the histopathological score including loss of epithelium and cellular architecture arrangements as described by Scaldaferri et al. [34] . The immunohistochemistry study was performed to study macrophage infiltration using rat monoclonal anti-F4/80 antibodies (A3-1) and ImmunoCruz™ rat ABC Staining System (Santa Cruz Biotechnology, TX, USA), following manufacturer's instructions. Briefly, paraffin-embedded colonic tissues were cut at 5-μm sections and incubated with blocking serum, followed by anti-F4/80 antibodies and biotinylated secondary antibodies. The sections were then counter stained with hematoxylin. The imageJ software (https:// imagej.nih.gov/ij/) [35] was used to quantify color segmentation of two-color staining, and macrophage infiltration.
Colon culture and cytokines quantification
Equal size of colon tissues were cut and cultured in 400 μL RPMI-1640 medium containing penicillin/streptomycin for 24 h. The cytokines levels in tissue culture supernatants and serum were quantified using ELISA kits (GenWay, CA, USA), following manufacturer's instructions.
Quantitative real-time PCR
Total RNA was isolated using RNeasy kit® (Qiagen, Hilden, Germany), and reverse transcribed in a thermal cycler using ReadyScript® cDNA Synthesis Mix (Sigma Aldrich). Amplification of cDNA was carried out in ViiA7 real-time PCR system with the following thermal profile (50°C for 2 min and 95°C for 10 min, then followed by 40 cycles of 95°C for 15 s and 60°C for 1 min). The TaqMan® Gene Expression of Cyp1a1 (Mm00487218_m1), AChE (Mm00477274_g1), Gapdh (Mm99999915_g1), and TaqMan® microRNA assay of has-miR-132 (ID:00457), has-miR-212 (ID:00515) and RNU6B (ID: 1093) were utilized in this study. System, kits and reagents for real-time PCR were purchased from Applied Biosystems (CA, USA). The relative gene expression was calculated using the comparative ΔΔCt method.
AChE activity and western blot
The lysates were prepared using RIPA Lysis Buffer System® (Santa Cruz Biotechnology), and protein concentration was quantified using BCA Proetin Assay® kit (Thermo Scientific, MA, USA). The lysates were fractionated using SDS-PAGE system (Bio-Rad, CA, USA). The AChE and β-actin proteins were detected using anti-rabbit polyclonal antibodies (Santa Cruz Biotechnology). The AChE catalytic activity was quantified using modified Ellman's method [21] . Briefly, the hydrolysis of ACh (Sigma Aldrich) was measured in the presence of specific butyrylcholinesterase inhibitor (tetraisopropylpyrophosphoramide, Sigma Aldrich). Light absorbance was measured spectrophotometrically at 405 nm at 10 min intervals.
Transfection
The CD4 + cells were isolated using MACS isolation kit (Miltenyi Biotec, Bergisch Gladash, Germany), following manufacturer's instructions, and macrophages were collected from peritoneal cavity after injecting 3% (w/v) Brewer thioglycollate medium (BD Biosciences, CA, USA). The antisense (as)-miR-132 and negative control were purchased
International Immunopharmacology 52 (2017) [342] [343] [344] [345] [346] [347] [348] [349] [350] [351] from Ambion (NY, USA). The primary cells were transfected with the oligonucleotides by 4D-Nuclefector device using their specific electroporation kits (Lonza, MD, USA) following manufacturer's instructions. The electroporated cells recovered for 6 h before medium change and stimulation. Transfection efficiency was confirmed by qPCR.
Silencing miR-132 in vivo
The locked nucleic acid (LNA) as-miR-132 or scramble oligonucleotides (Sigma-Proligo, TX, USA) were injected i.v. in the TCDDtreated CAC mice as described previously [21] . Mice received 3.5 mg of the as-miR-132 twice a day during DSS treatment. Efficiency of silencing miR-132 was confirmed by qPCR.
Statistics
The results are shown as mean ± SD of representative experiment out of three independent experiments produced similar results. The student's t-test was used to analyze the statistical significance between the means. Two-way ANOVA was used to test the statistical significance between DAI scores over CAC period. ⁎ P < 0.05 was considered significant.
Results
Exogenous Ahr agonists attenuate CAC pathogenesis
In previous studies, we found that activation of Ahr by TCDD ameliorates the EAE and breast cancer by inducing miR-132 [21, 27] . In the current study, we hypothesized that activation of Ahr by TCDD or DIM could ameliorate autoimmune inflammation and the associated colon cancer in chronic UC by inducing miR-132. Therefore, we first examined the effects of TCDD (1 μg) and DIM (25 μg) on the pathogenesis of AOM/DSS-induced murine model of CAC. The CAC was induced in mice by i.p. injection with AOM followed by three cycles of DSS (5 days) and water (16 days) (Fig. 1a) . The CAC mice were i.p. injected with TCDD, DIM or corn oil (Veh.) 2 days before DSS administration (Fig. 1a) . The TCDD-or DIM-treated mice showed significant resistance to CAC as presented by DAI score (Fig. 1b) . Induction of CAC increased the colon weight/length ratio and decreased the colon length (Fig. 1c, d ). These deteriorating effects of CAC on the colon were reversed with TCDD treatment, but not DIM treatment (Fig. 1c, d ). Activation of Ahr in vivo by TCDD or DIM was confirmed by quantifying Cyp1a1 mRNA in the colon, spleen and lymph nodes (LN) on the first day of DSS cycles ( Fig. S1) .
With regard to the colon tumorigenesis, induction of CAC in mice resulted in tumor nodules concentrated in the distal part of the colon (Fig. 1e ). Treating mice with TCDD or DIM decreased the number of tumor nodules compared with the Veh.-treated mice (Fig. 1f) . The tumor area and tumor nodule size were also reduced in TCDD-or DIMtreated CAC mice (Fig. 1g, h ). Moreover, Ahr agonists ameliorated the burden of CAC on the colon tissues and decreased the histopathological scores (Fig. 1h) .
TCDD and DIM ameliorate CAC by suppressing macrophage infiltration and pro-inflammatory cytokines
Macrophage infiltration contributes to CAC pathogenesis by secreting several pro-inflammatory cytokines [36] . Therefore, we examined the effects of Ahr agonists on macrophage infiltration within the colon mucosa by means of immunohistochemistry using anti-F4/80 antibodies. Quantification of F4/80 by color segmentation revealed that TCDD and DIM exerted obvious reductions in macrophage infiltration as presented by F4/80-positive cell per high power field (HPF) (Fig. 1i) . These results suggest that the suppressed macrophage infiltration contributed, at least partially, to the ameliorative effects of TCDD and DIM on CAC severity.
The pro-inflammatory cytokines are the key biomarkers of autoimmune inflammation and tissue damage in the colon [37] , and they modify the tumor microenvironment to enlarge tumor size in CAC [38] . In particular, the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, IFN-γ and IL-17 augment the pathogenesis of CAC, whereas the anti-inflammatory cytokine TGF-β has an opposing effect [38, 39] . Therefore, we examined the effects of TCDD and DIM on the levels of these proand anti-inflammatory cytokines. Interestingly, TCDD treatment altered all the examined cytokines by suppressing serum levels of TNF-α, IL-1β, IL-6, IFN-γ and IL-17 and enhancing that of TGF-β compared with Veh.-treated CAC mice (Fig. 2a) . On the other hand, DIM decreased IL-6 significantly, whereas the supressing effects of DIM on other pro-inflammatory cytokines did not reach the significance level (Fig. 2a) . These results indicate different mode of actions between TCDD and DIM on the pro-inflammatory cytokines. Compared with its effect on serum cytokines, TCDD suppressed the levels of TNF-α, IL-1β, IL-6, IFN-γ and IL-17 and enhanced that of TGF-β in the supernatant of whole colon culture (Fig. 2b) . In contrast, DIM exerted differential effects by suppressing the levels of TNF-α, IL-6 and IFN-γ and enhancing that of TGF-β in the supernatant of whole colon culture (Fig. 2b) . Collectively, our findings suggest that TCDD, and to a lesser extent DIM, ameliorate CAC by suppressing pro-inflammatory factors including macrophage infiltration and pro-inflammatory cytokines production.
TCDD-activated Ahr regulates the expression of miR-132 in CAC animals
Because miR-132 is regulated by Ahr [21, 27] , and is associated with UC [26] and colorectal cancer [17] , we studied the effects of both TCDD and DIM on miR-132 expression in CAC mice. Thus, we first assessed the relevance of miR-132 to the pathogenesis of CAC. As shown in (Fig. 3a) , induction of CAC in mice upregulated the expression of miR-132 in the colon, spleen and LN at the end of the CAC experimental period (day 63). Having found that miR-132 is upregulated at later stage of CAC development, we quantified its expression at earlier stages after the first (day 28) and second (day 49) DSS cycles. Similarly, miR-132 expression was upregulated in the colon, spleen and LN of CAC mice at earlier stages of CAC development (Fig. 3b, c) , which suggest that miR-132 is involved in CAC pathogenesis. Interestingly, treating CAC mice with TCDD boosted miR-132 expression in the examined tissues compared with the Veh.-treated CAC mice (Fig. 3a, b, c) . The DIM treatment enhanced miR-132 expression in the colon only at late stages of CAC development, but not at the earlier stage (Fig. 3a, b, c) .
The miR-132 and miR-212 are tandem members of a miRNA cluster named miR-212/132. These miRNAs share the same regulatory elements and target an overlapping set of genes [27, 40] . Therefore, we examined the effects of Ahr agonists on miR-212 in the colon, spleen and LN of the CAC mice. Consistent with the observations of miR-132, miR-212 was upregulated with induction of CAC and boosted with TCDD treatment (Fig. S2) . Additionally, TCDD and DIM upregulated the expression of miR-212/132 cluster in the cancer cells isolated from tumor nodules of the CAC mice (Fig. S2) . The results, unequivocally, indicate that TCDD regulates miR-212/132 cluster in CAC mice.
TCDD augments cholinergic anti-inflammation by inducing AChEtargeting miR-132
It has been shown that miR-132 induces cholinergic anti-inflammation by targeting acetylcholinesterase (AChE) [20, 21] , an enzyme that hydrolyzes acetylcholine (ACh) and abrogates its anti-inflammatory properties. Our current and previous findings on the regulatory role of agonist-activated Ahr on miR-132 prompted us to predict an implication of miR-132/AChE axis in the ameliorative effects of the Ahr agonists. To test this hypothesis, we studied the effects of TCDD and DIM on the gene expression of AChE at the sites of inflammation and immune activation. Inducing CAC in mice increased the mRNA and protein levels of AChE in the colon and spleen (Fig. 4a,  b) . Interestingly, TCDD robustly reversed these effects and reduced the AChE level to a comparable level with that of the normal control mice (Fig. 4a, b) . Although DIM treatment showed a tendency to suppress gene expression of AChE, such effect was insignificant (Fig.4a, b) . Taken together, these results suggest that TCDD induces a cholinergic anti-inflammatory action in the CAC mice. Therefore, TCDD was selected for further investigation.
The T cells and macrophages are the most frequently found immune cells in tumor microenvironment, and they are associated with CAC growth [41, 42, 43] . These cells produce ACh and AChE upon activation [21, 44, 31] . Therefore, we investigated the effects of TCDD on the hydrolysing activity of AChE on ACh. In T cells, activation of Ahr by TCDD reduced the hydrolysing activity of AChE in PHA-activated T cells at 24 and 36 h (Fig. 5a ). To confirm if the effect of TCDD on AChE activity was mediated by miR-132, we inhibited miR-132 using RNA interference in TCDD-treated T cells. Silencing miR-132 in T cells mitigated the suppressive effects of TCDD on AChE activity at 36 h (Fig. 5a ). In macrophages, treating the LPS-activated cells with TCDD exerted significant inhibitory effect on AChE activity, and silencing miR-132 alleviated the TCDD effect at 24 and 36 h (Fig. 5b) . Collectively, these 
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International Immunopharmacology 52 (2017) [342] [343] [344] [345] [346] [347] [348] [349] [350] [351] findings indicate that TCDD induces a cholinergic anti-inflammation in T cells and macrophages via augmenting miR-132 expression.
MiR-132 mediates the in vivo ameliorative effects of TCDD on CAC
Finally, to confirm that the ameliorative effect of TCDD on CAC was mediated by AChE-targeting miR-132, we silenced miR-132 in the TCDD-treated CAC mice. Inhibition of miR-132 in the TCDD-treated CAC mice abolished the ameliorative effects of TCDD on DAI score, and mitigated the suppressive effects of TCDD on the colon weight/length ratio (Fig. 6a, b) . Moreover, as-miR-132 treatment enhanced colon tumorigenesis in CAC mice compared to the TCDD treatment alone as presented by the number of tumor nodules and tumor area (Fig. 6c, d ). The efficiency of as-miR-132 in vivo was confirmed in the colon and spleen on day 49 (one day after third cycle of DSS) by quantitative realtime PCR (Fig. 6e) . These results indicate that miR-132 mediates the ameliorative effects of TCDD on CAC.
Next, we asked whether the ameliorative effects of TCDD on CAC was mediated by miR-132/AChE module. Silencing miR-132 in vivo increased the AChE level in the colon and spleen compared with the TCDD-treated CAC mice (Fig. 6f) , suggesting that TCDD augments cholinergic anti-inflammation in CAC mice by inducing miR-132 expression. It has been shown that the cholinergic anti-inflammation is manifested by suppressed production of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 [21] . Therefore, we investigated the role of miR-132 in the suppressive effects of TCDD on these cytokines. Quantifying serum levels of TNF-α, IL-1β and IL-6 showed that silencing of miR-132 abolished the TCDD effect and restored cytokines production (Fig. 6g) . These findings revealed that TCDD potentiates cholinergic anti-inflammation in CAC mice by inducing AChE-targeting miR-132. In contrast, silencing miR-132 in TCDD-treated CAC mice did not exert significant effect on IFN-γ, IL-17 and TGF-β (Fig. 6g) . 
Discussion
The CAC represents a major complication in the patients with UC disease, one of the most common forms of IBD. It is increasingly evident that Ahr plays a critical role in CAC pathogenesis [45, 46] . Activation of Ahr by exogenous ligands alleviates autoimmune inflammation in UC [47] , and the associated tumorigenesis [45, 48] . In addition, several miRNAs are implicated in the development of CAC [49] , and modulation of these miRNAs provides therapeutic potential [50] . However, the axis of Ahr/miRNA in CAC has not been investigated. Recently, we provided first evidences that miR-132 mediates the anti-inflammatory and anticancer properties of the potent Ahr agonist TCDD [21, 27] . Herein, we demonstrated that TCDD-or DIM-activated Ahr ameliorates CAC in mice by repressing pro-inflammatory mediators. In addition, the findings revealed that TCDD, but not DIM, augments cholinergic antiinflammation by inducing AChE-targeting miR-132. This anti-inflammatory effect was characterized by suppressed production of proinflammatory cytokines.
The Ahr is an environmentally-responsive transcription factor activated by wide range of natural and synthetic ligands such as TCDD, Fig. 4 . TCDD, but not DIM, suppresses AChE level in AOM/DSSinduced CAC in mice. mRNA and protein expressions of AChE in a colons and b spleens of healthy Control and vehicle (Veh.)-, TCDDand DIM treated CAC mice 63 days after CAC induction. mRNA and protein expressions were quantified by quantitative real-time PCR and western blot, respectively, and presented relative to the healthy Control. Data are shown as means ± SD from representative experiment out of three independent experiments produced similar results. *P < 0.05; n = 6 mice per group. 
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International Immunopharmacology 52 (2017) [342] [343] [344] [345] [346] [347] [348] [349] [350] [351] DIM and I3C [51] . Upon ligation, Ahr exerts prominent ameliorative effect on autoimmune inflammation [21] , and suppresses certain cancer types including colon cancer [52] . In the current study, we found that TCDD and DIM ameliorate autoimmune inflammation and tumorigenesis in CAC mice and protect colon architecture. The TCDD, and to a lesser extent DIM, suppressed macrophages infiltration and production of TNF-α, IL-1β, IL-6 and IL-17, and enhanced the production of TGF-β. These observations are supported by previous findings showing that activation of Ahr by DIM attentuates UC and the associated tumorigenesis in AOM/DSS model of CAC [47] . This ameliorative effect of DIM was mediated by inhibiton of myeloperoxidase activity, production of prostaglandin E2 production, nitric oxide and pro-inflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-17 [47] . Furthermore, deletion of Ahr in mice increases tumor incidence in AOM/DSS-induced CAC, whereas activation of Ahr by I3C suppresses tumor incidence and multiplicity of cancer [31] . However, the implication of miRNA in such ameliorative effect of Ahr has not been reported yet. It has been demonstrated that miR-132 augments cholinergic antiinflammation by targeting AChE in LPS-induced inflammation [20] . More recently, we showed that TCDD-activated Ahr induces AChEtargeting miR-132 in autoimmune encephalomyelitis to augment cholinergic anti-inflammation manifested by suppressed TNF-α, IL-1β, and IL-6 levels [21] . In the current study, we showed that TCDD, but not DIM, induces AChE-targeting miR-132 to augment cholinergic anti-inflammation characterized by inhibition of pro-inflammatory mediators including TNF-α, IL-1β, IL-6 and AChE. Notably, both miR-132 and its target AChE are upregulated at early and late stages of CAC development, suggesting a rheostat function of miR-132 by targeting AChE and initiating cholinergic anti-inflammation. Collectively, these findings indicate that TCDD augments a cholinergic anti-inflammation in CAC by shifting the balance toward miR-132.
The T cells and macrophages, and possibly other immune cells, enhance CAC growth by secreting pro-inflammatory cytokines such as IL-6, IL-11, TNF-α and IL-1β [42, 53] . These cells produce ACh that binds to the α7 nicotinic receptor [54, 20] , which in turn suppresses production of pro-inflammatory cytokine via inhibition of NFκB [23] . It has been shown that activation of the α7 nicotinic receptor in macrophages suppresses the production of TNF-α and IL-1β [55] , and inhibition of AChE activity in T cells suppresses the production of TNF-α [56] . Moreover, macrophages from transgenic mice overexpressing AChE without miR recognition elements produce higher levels of TNF-α, IL-6 and IL-12 in response to LPS, even with upregulation of miR-132 [20] .
We found, consistently, that TCDD suppresses the production of TNF-α, IL-1β and IL-6, whereas restoring AChE level by silencing miR-132 reinstates their production. Taken together, we concluded that the suppressed levels of TNF-α, IL-1β and IL-6 were component of the miR-132-mediated cholinergic anti-inflammation. On the other hand, the effect of TCDD on IFN-γ, IL-17 and TGF-β were not components of the TCDD-augmented cholinergic anti-inflammation in CAC, as confirmed by inhibition of miR-132. These findings may be supported by previous studies, which showed that the differentiation of T helper 1(Th1), Th17 and Treg cells in EAE mice is not a component of the TCDD-augmented cholinergic anti-inflammation [21] . Although silencing miR-132 revealed that the cholinergic anti-inflammation play a vital role in mediating the ameliorative effect of TCDD on CAC severity, TCDD alleviates autoimmune inflammation in UC by enhancing the differentiation of Treg cells [57] . Therefore, we suggest that TCDD-activated Ahr ameliorates CAC at least by two mechanisms, which includes augmenting miR-132-mediated cholinergic anti-inflammation and differentiation of Treg cells.
Notably, the DIM exerted inferior suppressive effects compared to those of TCDD on CAC severity as well as miR-132 and AChE expressions. In addition, the effect of DIM on the pro-and anti-inflammatory cytokines were obvious only in the whole colon culture. These discrepancies may be attributed to the chemical stability and longer halflife of TCDD that sustain strong Ahr activation [27] . In addition, the antioxidant property of the flavonoids, including DIM, optimizes the microenvironment to enhance the general functions of the cells [58] . Such observations may partially elucidate the suppressive effects of DIM on the production of examined cytokines from colon tissues.
In summary, we found that TCDD-activated Ahr regulates the expression of miR-132 and ameliorates autoimmune inflammation and tumorigenesis in CAC via augmenting cholinergic anti-inflammation. However, the TCDD-augmented cholinergic anti-inflammation is not solely responsible for the ameliorative effects of TCDD on CAC, as it alleviates autoimmune inflammation in UC by promoting Treg cell differentiation [57] . The results of this Ahr-based study lends an interest to the therapeutic potential of miR-132 in CAC patients.
